For example, it has been reported that the rapidly-reversible acetylcholinesterase (AChE) inhibitors (donepezil, galantamine and tacrine), which were intended for decreasing AChE activity, were found to significantly increase AChE activity and protein levels in the cerebrospinal fluid (CSF) of AD patients after long-term (1 year) treatment [5]. This evidence concerns the gene ACHE and Alzheimer disease.